Spinraza: A Model Approval

The approval of Biogen’s Spinraza for spinal muscular atrophy is a model case for demonstrating FDA’s speed in getting a compelling new therapy to market, the value of a responsive sponsor, and engaging positively with patient advocates in the storm of a controversial approval decision by the neurology division on a different product.